Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial중환자실에 입원한 COVID-19 환자의 혈전성 사건, 체외막 산소 치료 또는 사망률에 대한 중간 용량 대 표준 용량 예방적 항응고제의 효과: The INSPIRATION 무작위 임상 시험Randomized Controlled Trial Published on 2021-04-272022-09-25 Journal: JAMA [Category] 임상, 진단, 치료법, [키워드] age anticoagulation Antithrombotic assigned bleeding clearance clinical COVID-19 creatinine criteria Critically ill patient dose Effect Efficacy eligibility criteria evaluate the effect event Extracorporeal extracorporeal membrane oxygenation factorial design Final Follow-up Hypothesis ICU intensity intensive care intermediate-dose group Iran Limited Major major bleeding margin matching placebo median Modification Mortality occurred Odds ratio outcome Patient patients with COVID-19 performed Platelet primary analysis Primary outcome Prophylactic Prophylaxis randomized patient randomized patients randomized trial recruited reported risk significant difference Standard-dose Support therapy thrombosis Treatment venous with COVID-19 women [DOI] 10.1001/jama.2021.4152 PMC 바로가기 [Article Type] Randomized Controlled Trial
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trialCOVID-19(FLARE) 외래 환자의 조기 항바이러스 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-03-082022-09-01 Journal: Trials [Category] SARS, 임상, 진단, 치료기술, 치료제, [키워드] 24 hours 48 hour 48 hours absence admitted to ICU aetiology age ALT Analysis Anosmia anticipated antiviral therapy Antiviral treatment antivirals Appendix Arm arrhythmia AST Asthma Asymptomatic Autoimmune blinded to treatment Blinding blood sample BMI Breastfeeding childbearing potential Cholangitis chronic chronic hepatitis Chronic kidney disease chronic liver disease chronic respiratory disease cirrhosis clinical condition collected combination therapy Comorbidity concealed Concomitant concomitant medications conducted COPD coryza cough COVID-19 COVID-19 disease COVID-19 vaccine criteria current Date Day decrease defined Deleterious detectable diabetes died disease dissemination dose double-blind Duration early treatment effective EGFR element enrolled enrolment Ethnicity examined exclusion criteria factorial design Favipiravir female female participant Fever followed by Free Gender headache heart disease Hepatitis hepatotoxicity HIV infection hospital hospitalisation hypersensitivity hypertension in viral include inclusion criteria ingredient investigator investigators Ischaemic heart disease Kidney disease liver Liver disease London Lopinavir Lopinavir/ritonavir malaise male participant male participants measure medication Mutation myalgia Myocardial infarction no symptom non-hospitalised not limited number obesity objective observational studies observational study oral outcome Outpatient outpatients participant Participants partner percentage pharmacokinetic phase IIa Placebo placebo-controlled placebo-controlled trial positive presence or absence Primary outcome Proportion of participant Protease inhibitor protocol randomised randomised controlled trial Rate Registered Registration respiratory Respiratory disease risk Ritonavir Safety Saliva saliva samples Sample size SARS-CoV-2 secondary Secondary outcomes Shortness of breath smoker smoking smoking status Stage status steatohepatitis Stool Study protocol supplementary material Symptom symptom onset symptomatic tested therapy Toxicity Treatment treatment allocation Trial trial medication Trial registration undetectable United Kingdom upper respiratory tract vaccine trial valvular valvular heart disease Viral Viral load website with COVID-19 [DOI] 10.1186/s13063-021-05139-2 PMC 바로가기 [Article Type] Letter
Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2; Antiviral Screening and Molecular Docking StudiesArticle Published on 2021-02-262022-10-28 Journal: Pharmaceutics [Category] COVID-19, [키워드] activity addition Anti-viral bee venom carried cellular characterization China Combination complex component Concentration COVID-19 COVID-19 pandemic Critical docking Efficacy evaluate factorial design Factors Health IC50 in vitro melittin Nanoparticles outbreak pandemic diseases Particle predicted protease repurposing responses SARS-CoV-2 SARS-CoV-2 virus Screening selected shown sitagliptin target cell the SARS-CoV-2 were assessed [DOI] 10.3390/pharmaceutics13030307 PMC 바로가기 [Article Type] Article
Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 VirusArticle Published on 2021-02-242022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] 1:1 3CL 3CL Protease Acetate activity acute respiratory syndrome addition Antiviral binding affinity carried cause cellular characterization China Clinical efficacy clinical study complex component Concentration coronavirus Coronavirus replication COVID COVID-19 COVID-19 pandemic criteria docking Efficacy epithelial cell evaluate factorial design Factors FDA-approved drugs Glatiramer acetate half-maximal inhibitory concentration Health IC50 investigated Nanoparticles outbreak Prevent protease protease inhibition required responses SARS-CoV-2 selected shown sitagliptin target cell TEM the SARS-CoV-2 virus transmission electron microscopy treat VERO-E6 virus were assessed [DOI] 10.3390/ph14030178 PMC 바로가기 [Article Type] Article
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studiesCOVID-19 중증 환자에서 중간 용량 대 표준 용량 예방적 항응고제 및 스타틴 요법 대 위약: INSPIRATION/INSPIRATION-S 연구의 이론적 근거 및 설계Article Published on 2020-12-012022-09-11 Journal: Thrombosis research [Category] 임상, [키워드] all-cause mortality Analysis anticoagulation antithrombotic therapy Arterial thrombosis atorvastatin bleeding Chain Reaction cohorts Composite Controlled trial coronavirus disease Coronavirus disease 2019 COVID-19 death double-blind eligibility criteria Enrollment Exploratory analyses Exploratory analysis extracorporeal membrane oxygenation factorial design hallmark hallmarks help hypothese Hypothesis immune response include independent inferiority inspiration intensity intention-to-treat intermediate limit liver enzyme liver enzymes major bleeding management manifestation matching placebo modified intention-to-treat Myopathy non-inferiority non-inferiority margin normal limit Odds ratio open open label Patient patients with COVID-19 per-protocol performed Placebo Platelet Platelet count polymerase chain polymerase chain reaction Prevent primary endpoint Prophylactic prophylactic anticoagulation question randomization Randomized Randomized controlled trial rationale Result reverse transcription reverse transcription polymerase chain reaction safety endpoint screened secondary endpoint Standard dose Standard-dose statin Stratified randomization subgroup tested therapy thrombocytopenia thrombosis thrombotic event Thrombotic events undergo Venous Thromboembolism Ventilator-free days VTE [DOI] 10.1016/j.thromres.2020.09.027 PMC 바로가기 [Article Type] Article
Handwashing and Detergent Treatment Greatly Reduce SARS-CoV-2 Viral Load on Halloween Candy Handled by COVID-19 PatientsObservation Published on 2020-11-172022-10-29 Journal: mSystems [Category] COVID-19, [키워드] activities activity acute respiratory syndrome Aerosols Asymptomatic candy children Combination coronavirus coughing COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 patients Deprivation detergent diagnosed enrolled extreme factorial design fomite Halloween handling handwashing Impact isothermal amplification LAMP load mental health pandemic parents Patient precautions protocol qPCR quantitative PCR reduced respiratory droplet risk risk of transmission RT-qPCR SARS-CoV-2 SARS-CoV-2 transmission subject surface swab symptomatic transcriptase Transmission transmitted Treatment Viral load viral RNA load Viral transmission was reduced [DOI] 10.1128/mSystems.01074-20 PMC 바로가기 [Article Type] Observation
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-06-032022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 24 hour acute respiratory distress syndrome addition Administered Anakinra anti-IL-1 anti-IL-6 anti-IL-6 receptor antibody Bacterial Belgium binding blinded blockade Blood characterized chest X-ray chimeric clinical Clinical improvement Combination composed Coronavirus infection COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 patient CT scan death defined discharge dissemination dose drug Effectiveness element EudraCT excluded experimental arm factorial design Fungal infection hospital hospital discharge Hospitalized hospitals hypoxia hypoxic respiratory failure ICU IL-1 IL-6 IL-6 blockade IL-6 receptor interleukin 1 blockade interleukin 6 blockade Intravenous injection Invasive mechanical ventilation LDH lymphopenia mechanical ventilation non-invasive ventilation number objective on mechanical ventilation open label Open-label outcome oxygen Oxygenation paO2/fiO2 participant Participants Patient patients with COVID-19 Phase 3 primary end point protocol randomisation randomised randomised controlled trial randomization Randomized receive receptor recruited recruitment Registered response Sample size Serum ferritin siltuximab standard care Standard of care status Study protocol subcutaneous injection supplemental oxygen syndrome System systemic cytokine systemic cytokine release syndrome Tocilizumab treated Trial usual care was selected Web website [DOI] 10.1186/s13063-020-04453-5 PMC 바로가기 [Article Type] Letter
Risk factors associated with exposure to bovine respiratory disease pathogens during the peri-weaning period in dairy bull calvesResearch Article Published on 2018-02-272022-10-28 Journal: BMC veterinary research [Category] Coronavirus, [키워드] Analysis animal antibodies antibody association bovine Bovine respiratory disease Calves cause changes in Clinical data Clustering Cohort collected correlated dairy death decrease demonstrated exposure Factor factorial design haptoglobin identify levels of antibody Linear regression model management marker pathogen Pathogens random recorded Respiratory disease Result risk factor S/P serological response significant increases in significantly significantly lower study population were used [DOI] 10.1186/s12917-018-1372-9 PMC 바로가기 [Article Type] Research Article
Enhancement of the topical tolnaftate delivery for the treatment of tinea pedis via provesicular gel systemsArticle Published on 2017-12-312024-08-30 Journal: J Liposome Res [Category] 백선증, [키워드] Antifungal drug confocal laser scanning microscopy factorial design permeation enhancing proniosomes. PMC 바로가기
A Randomized Longitudinal Factorial Design to Assess Malaria Vector Control and Disease Management Interventions in Rural Tanzania농촌 탄자니아에서 말라리아 매개체 통제 및 질병 관리 개입을 평가하기 위한 무작위 종단적 요인 설계Article Published on 2014-05-162024-08-13 Journal: International Journal of Environmental Research and Public Health [Category] 말라리아, [키워드] community health delivery experiments disease management factorial design Implementation science Larviciding malaria Tanzania vector control [DOI] 10.3390/ijerph110505317 PMC 바로가기 [Article Type] Article